Avalo Therapeutics
AVTX
29 hedge funds and large institutions have $63.2M invested in Avalo Therapeutics in 2024 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.
557% more capital invested
Capital invested by funds: $9.62M → $63.2M (+$53.6M)
400% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 2
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
38% more funds holding
Funds holding: 21 → 29 (+8)
6.24% less ownership
Funds ownership: 74.86% → 68.63% (-6.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$9.97M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$9.97M |
| 3 |
O
OrbiMed
New York
|
+$9.97M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$9.97M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
+$9.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$7K |
| 2 |
BCV
Banque Cantonale Vaudoise
Lausanne,
Switzerland
|
-$4K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$10 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $10 | – | – | – |
|
|
JIP
27
Jaffetilchin Investment Partners
Tampa,
Florida
| $10 | +$10 | +1 | New |
|
|
28
Fidelity Investments
Boston,
Massachusetts
| $9 | -$10 | -1 | -50% |
|
|
29
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$7K | -590 | Closed |
|
|
BCV
30
Banque Cantonale Vaudoise
Lausanne,
Switzerland
| – | -$4K | -338 | Closed |
|
|
AW
31
Avion Wealth
The Woodlands,
Texas
| – | +$52 | +5 | New |
|
AVTX Hedge Fund Activity: Q3 2024 in Review
29 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q3 2024, worth a combined $63.2M — up 557% from $9.62M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new AVTX positions and 2 closed out — a net gain of 8 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $9.97M. The largest seller was Royal Bank of Canada, exiting entirely with an estimated $7K sold.
- 29 institutional investors held Avalo Therapeutics (AVTX) as of Q3 2024, up from 21 in Q2 2024.
- Funds reported $63.2M of Avalo Therapeutics stock for Q3 2024, up 557% quarter-over-quarter.
- 10 funds opened new Avalo Therapeutics positions in Q3 2024 and 2 closed out, a net change of +8 holders.
- The largest Avalo Therapeutics buyer in Q3 2024 was BVF Inc, an estimated $9.97M added.
- The largest Avalo Therapeutics seller in Q3 2024 was Royal Bank of Canada, an estimated $7K sold.
Based on aggregated 13F filings for Q3 2024.